


I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to:
Director – U.S. Patent and Trademark Office, Washington, D.C. 20231 on this 21st day of December, 2001.

By


(Signature of person mailing)
Janice M. Denison
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **STEPHANIE K. HALL, ET AL:**

APPLICATION NO.: **TO BE ASSIGNED**

: Examiner: **TO BE ASSIGNED**

FILING DATE: **HEREWITH**

: Group Art Unit: **TO BE ASSIGNED**

TITLE: **METHODS AND REAGENTS FOR
DETECTING INCREASED RISK OF
DEVELOPING AN INFLAMMATORY
DISORDER**

Director – U.S. Patent and Trademark Office
Washington, D.C. 20231

STATEMENT REGARDING SUBMISSION
OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to
the written sequence listing.

Respectfully submitted,

Date:

12/21/01


Jennifer A. Kispert

Attorney for Applicant(s)
Reg. No. 40,049

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5747

EXPRESS MAIL NO. EL911725504US